BACKGROUND: Biliary radiofrequency ablation (RFA) using the Habib™ EndoHBP catheter is a new endoscopic palliation therapy for malignant biliary obstruction. The aim of this study was to assess the feasibility and safety of this technique. METHODS: In this nationwide retrospective study of prospectively collected clinical data, all patients treated by biliary RFA in Austria between November 2010 and December 2012 were included. Procedure-related complications, adverse events within 30 days post-intervention, stent patency, and mortality rates were investigated. RESULTS: A total of 58 patients (31 male, 27 female, median age 75 years) underwent 84 RFA procedures at 11 Austrian referral centers for biliary endoscopy. The predominant underlying condition was Klatskin tumor (45 of 58 cases). All 84 RFA procedures were feasible without technical problems. A partial liver infarction was induced by RFA in a 49-year-old Klatskin tumor patient. During 30 days after each RFA procedure, five cases of cholangitis, three cases of hemobilia, two cases of cholangiosepsis, and one case each of gallbladder empyema, hepatic coma, and newly diagnosed left bundle branch block occurred. Median stent patency after last electively performed RFA was 170 days (95 % CI 63-277) and was almost significantly different between metal and plastic stenting (218 vs. 115 days; p = 0.051). Median survival was 10.6 months (95 % CI 6.9-14.4) from the time of the first RFA in each patient and 17.9 months (95 % CI 10.3-25.6) from the time of initial diagnosis. CONCLUSIONS: Except for one severe interventional complication (hepatic infarct), RFA presented as a technically feasible and safe therapeutic option for the palliative treatment of malignant biliary obstruction. The good results of stent patency and survival in this study should be proven in prospective (controlled) trials to further quantify the efficacy of this promising new technique.
BACKGROUND: Biliary radiofrequency ablation (RFA) using the Habib™ EndoHBP catheter is a new endoscopic palliation therapy for malignant biliary obstruction. The aim of this study was to assess the feasibility and safety of this technique. METHODS: In this nationwide retrospective study of prospectively collected clinical data, all patients treated by biliary RFA in Austria between November 2010 and December 2012 were included. Procedure-related complications, adverse events within 30 days post-intervention, stent patency, and mortality rates were investigated. RESULTS: A total of 58 patients (31 male, 27 female, median age 75 years) underwent 84 RFA procedures at 11 Austrian referral centers for biliary endoscopy. The predominant underlying condition was Klatskin tumor (45 of 58 cases). All 84 RFA procedures were feasible without technical problems. A partial liver infarction was induced by RFA in a 49-year-old Klatskin tumorpatient. During 30 days after each RFA procedure, five cases of cholangitis, three cases of hemobilia, two cases of cholangiosepsis, and one case each of gallbladder empyema, hepatic coma, and newly diagnosed left bundle branch block occurred. Median stent patency after last electively performed RFA was 170 days (95 % CI 63-277) and was almost significantly different between metal and plastic stenting (218 vs. 115 days; p = 0.051). Median survival was 10.6 months (95 % CI 6.9-14.4) from the time of the first RFA in each patient and 17.9 months (95 % CI 10.3-25.6) from the time of initial diagnosis. CONCLUSIONS: Except for one severe interventional complication (hepatic infarct), RFA presented as a technically feasible and safe therapeutic option for the palliative treatment of malignant biliary obstruction. The good results of stent patency and survival in this study should be proven in prospective (controlled) trials to further quantify the efficacy of this promising new technique.
Authors: J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó Journal: Aliment Pharmacol Ther Date: 2011-09-20 Impact factor: 8.171
Authors: Franz Ludwig Dumoulin; Thomas Gerhardt; Sybille Fuchs; Christian Scheurlen; Michael Neubrand; Günter Layer; Tilman Sauerbruch Journal: Gastrointest Endosc Date: 2003-06 Impact factor: 9.427
Authors: John L S Cheng; Marco J Bruno; Jacques J Bergman; Erik A Rauws; Guido N Tytgat; Kees Huibregtse Journal: Gastrointest Endosc Date: 2002-07 Impact factor: 9.427
Authors: Aymeric Becq; Marine Camus; Gabriel Rahmi; Vincent de Parades; Philippe Marteau; Xavier Dray Journal: United European Gastroenterol J Date: 2015-08 Impact factor: 4.623
Authors: Werner Dolak; Hubert Schwaighofer; Brigitte Hellmich; Bernhard Stadler; Georg Spaun; Wolfgang Plieschnegger; Arnold Hebenstreit; Jutta Weber-Eibel; Franz Siebert; Klaus Emmanuel; Peter Knoflach; Michael Gschwantler; Wolfgang Vogel; Michael Trauner; Andreas Püspök Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623
Authors: Reem Z Sharaiha; Amrita Sethi; Kristen R Weaver; Tamas A Gonda; Raj J Shah; Norio Fukami; Prashant Kedia; Nikhil A Kumta; Carlos M Rondon Clavo; Michael D Saunders; Jorge Cerecedo-Rodriguez; Paola Figueroa Barojas; Jessica L Widmer; Monica Gaidhane; William R Brugge; Michel Kahaleh Journal: Dig Dis Sci Date: 2015-02-21 Impact factor: 3.199
Authors: Roberta Rea; Francesco Maria Di Matteo; Margareth Martino; Monica Pandolfi; Paola Saccomandi; Carla Rabitti; Anna Crescenzi; Guido Costamagna Journal: Lasers Med Sci Date: 2017-06-30 Impact factor: 3.161
Authors: Andrea Oliver Tal; Johannes Vermehren; Mireen Friedrich-Rust; Jörg Bojunga; Christoph Sarrazin; Stefan Zeuzem; Jörg Trojan; Jörg Gerhard Albert Journal: World J Gastrointest Endosc Date: 2014-01-16